Physician profile
Robert B Ash
NPI 1720073885
$4,250.74
in general payments reported to CMS, 2019-2025
22 companies · $779 in 2025
The $779 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $221 · 2021: $292 · 2022: $246 · 2023: $928 · 2024: $1,249 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.85 |
| Education | $139.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $802.96 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $690.09 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $371.07 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $305.51 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $296.08 | 2019-2025 | Ilumya |
| Leo Pharma INC. | $277.55 | 2019-2025 | Adbry |
| Lilly USA, LLC | $253.22 | 2019-2024 | Taltz |
| Regeneron Healthcare Solutions, INC. | $252.48 | 2023-2025 | Dupixent |
| Genzyme Corporation | $217.80 | 2020-2024 | |
| Organogenesis INC. | $198.87 | 2023-2025 | Novachor, Puraply, Puraply Wound Matrix |
| Ucb, INC. | $189.08 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $100.10 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $53.16 | 2019-2025 | Sotyktu |
| Incyte Corporation | $51.78 | 2023-2025 | Opzelura |
| Pfizer INC. | $43.49 | 2019-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.53 | 2023-2024 | Spevigo |
| Kyowa Kirin, INC. | $22.39 | 2025 | |
| Genentech USA, INC. | $22.11 | 2024 | Xolair |
| Galderma Laboratories, L.P. | $18.55 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $15.83 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $15.39 | 2025 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.